Market capitalization | $25.29m |
Enterprise Value | $35.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 58.95 |
P/S ratio (TTM) P/S ratio | 42.15 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 135.43% |
Revenue (TTM) Revenue | $600.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Pluristem Therapeutics Inc.:
1 Analyst has issued a forecast Pluristem Therapeutics Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 0.60 0.60 |
140%
140%
|
|
Gross Profit | 0.22 0.22 |
375%
375%
|
|
EBITDA | -22 -22 |
14%
14%
|
EBIT (Operating Income) EBIT | -22 -22 |
14%
14%
|
Net Profit | -22 -22 |
20%
20%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Head office | United States |
CEO | Yaky Yanay |
Employees | 118 |
Founded | 2001 |
Website | www.pluri-biotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.